Royalty Revenue
Our royalty revenues have grown significantly over the last several years and we expect continued growth before the expiration of our Queen et al patents in December 2014.
- In 2010, the largest royalties were from sales of Avastin® and Herceptin®
- Royalties from sales of Avastin® and Lucentis® increased more than 35% in 2010 as compared with 2009
- Other commercialized products include Mylotarg® and Actemra®
- Licensees’ product pipelines include new indications for Avastin and Lucentis, both in Phase 3, and Phase 3 Alzheimer’s disease products from Lilly and Wyeth
